These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 27391386)

  • 21. Allopurinol, benzbromarone and risk of coronary heart disease in gout patients: A population-based study.
    Lin HC; Daimon M; Wang CH; Ho Y; Uang YS; Chiang SJ; Wang LH
    Int J Cardiol; 2017 Apr; 233():85-90. PubMed ID: 28202260
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Hyperuricemia and gout--treatment].
    Gröbner W; Walter-Sack I
    Dtsch Med Wochenschr; 2002 Feb; 127(5):210-3. PubMed ID: 11821994
    [No Abstract]   [Full Text] [Related]  

  • 23. Improvement of renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts.
    Perez-Ruiz F; Calabozo M; Herrero-Beites AM; García-Erauskin G; Pijoan JI
    Nephron; 2000 Nov; 86(3):287-91. PubMed ID: 11096285
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
    Chohan S; Becker MA; MacDonald PA; Chefo S; Jackson RL
    Arthritis Care Res (Hoboken); 2012 Feb; 64(2):256-61. PubMed ID: 22052584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Associations between urate-lowering therapy and the risk of type 2 diabetes mellitus.
    Chang HW; Lin YW; Lin MH; Lan YC; Wang RY
    PLoS One; 2019; 14(1):e0210085. PubMed ID: 30615649
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Major unanswered questions in the clinical gout field.
    Stamp LK
    Curr Opin Rheumatol; 2017 Mar; 29(2):171-177. PubMed ID: 27926541
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population.
    Pui K; Gow PJ; Dalbeth N
    J Rheumatol; 2013 Jun; 40(6):872-6. PubMed ID: 23457380
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adherence and persistence to urate-lowering therapies in the Irish setting.
    McGowan B; Bennett K; Silke C; Whelan B
    Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of urate-lowering therapies on renal handling of uric acid.
    Ma L; Wei L; Chen H; Zhang Z; Yu Q; Ji Z; Jiang L
    Clin Rheumatol; 2016 Jan; 35(1):133-41. PubMed ID: 25373449
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of Conventional Uric Acid-Lowering Therapy on Monosodium Urate Crystal Deposits.
    Ellmann H; Bayat S; Araujo E; Manger B; Kleyer A; Cavallaro A; Lell M; Schenker H; Simon D; Tascilar K; Baraf HSB; Schett G; Rech J
    Arthritis Rheumatol; 2020 Jan; 72(1):150-156. PubMed ID: 31353871
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of uric acid-lowering therapy on hypercholesterolemia and hypertriglyceridemia in gouty patients.
    Wu J; Zhang YP; Qu Y; Jie LG; Deng JX; Yu QH
    Int J Rheum Dis; 2019 Aug; 22(8):1445-1451. PubMed ID: 31317680
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stronger Uricosuric Effects of the Novel Selective URAT1 Inhibitor UR-1102 Lowered Plasma Urate in Tufted Capuchin Monkeys to a Greater Extent than Benzbromarone.
    Ahn SO; Ohtomo S; Kiyokawa J; Nakagawa T; Yamane M; Lee KJ; Kim KH; Kim BH; Tanaka J; Kawabe Y; Horiba N
    J Pharmacol Exp Ther; 2016 Apr; 357(1):157-66. PubMed ID: 26907620
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study).
    Bardin T; Keenan RT; Khanna PP; Kopicko J; Fung M; Bhakta N; Adler S; Storgard C; Baumgartner S; So A
    Ann Rheum Dis; 2017 May; 76(5):811-820. PubMed ID: 27821644
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of benzbromarone versus febuxostat in gouty patients: a retrospective study.
    Liu D; Zhou B; Li Z; Zhang Z; Dai X; Ji Z; Chen H; Sun Y; Jiang L
    Clin Rheumatol; 2022 Jul; 41(7):2121-2128. PubMed ID: 35229198
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current management of gout in patients unresponsive or allergic to allopurinol.
    Bardin T
    Joint Bone Spine; 2004 Nov; 71(6):481-5. PubMed ID: 15589427
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Benzbromarone in the treatment of gout.
    Azevedo VF; Kos IA; Vargas-Santos AB; da Rocha Castelar Pinheiro G; Dos Santos Paiva E
    Adv Rheumatol; 2019 Aug; 59(1):37. PubMed ID: 31391099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Urate lowering therapies in the treatment of gout: a systematic review and meta-analysis.
    Borghi C; Perez-Ruiz F
    Eur Rev Med Pharmacol Sci; 2016 Mar; 20(5):983-92. PubMed ID: 27010159
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis.
    Halpern R; Mody RR; Fuldeore MJ; Patel PA; Mikuls TR
    Curr Med Res Opin; 2009 Jul; 25(7):1711-9. PubMed ID: 19485724
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.
    Hatoum H; Khanna D; Lin SJ; Akhras KS; Shiozawa A; Khanna P
    Postgrad Med; 2014 Mar; 126(2):65-75. PubMed ID: 24685969
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [How to select and use urate lowering agents for hyperuricemia].
    Yamanaka H
    Nihon Rinsho; 1996 Dec; 54(12):3261-5. PubMed ID: 8976102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.